{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T04:42:43Z","timestamp":1793421763540,"version":"4.5.0"},"reference-count":120,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40263-025-01244-x","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T10:41:19Z","timestamp":1762166479000},"page":"165-180","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Sodium Channel Inhibitors in Clinical Development for Pain Management: A Focused Review"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7638-7470","authenticated-orcid":false,"given":"Crystal","family":"Banh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-9093-6998","authenticated-orcid":false,"given":"Aleksandar","family":"Sic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8028-1495","authenticated-orcid":false,"given":"Nebojsa Nick","family":"Knezevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"issue":"4","key":"1244_CR1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.23992","volume":"14","author":"P Castroman","year":"2022","unstructured":"Castroman P, Quiroga O, Mayoral Rojals V, et al. Reimagining how we treat acute pain: a narrative review. Cureus. 2022;14(4):e23992. https:\/\/doi.org\/10.7759\/cureus.23992.","journal-title":"Cureus."},{"issue":"1","key":"1244_CR2","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1097\/j.pain.0000000000001365","volume":"160","author":"J Scholz","year":"2019","unstructured":"Scholz J, Finnerup NB, Attal N, et al. The IASP classification of chronic pain for ICD-11: chronic neuropathic pain. Pain. 2019;160(1):53\u20139. https:\/\/doi.org\/10.1097\/j.pain.0000000000001365.","journal-title":"Pain"},{"key":"1244_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.2","volume":"3","author":"L Colloca","year":"2017","unstructured":"Colloca L, Ludman T, Bouhassira D, et al. Neuropathic pain. Nat Rev Dis Primers. 2017;3:17002. https:\/\/doi.org\/10.1038\/nrdp.2017.2.","journal-title":"Nat Rev Dis Primers"},{"issue":"5","key":"1244_CR4","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1097\/ACO.0000000000000225","volume":"28","author":"DB Gordon","year":"2015","unstructured":"Gordon DB. Acute pain assessment tools: let us move beyond simple pain ratings. Curr Opin Anaesthesiol. 2015;28(5):565\u20139. https:\/\/doi.org\/10.1097\/ACO.0000000000000225.","journal-title":"Curr Opin Anaesthesiol"},{"key":"1244_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2023.108546","volume":"251","author":"M Thouaye","year":"2023","unstructured":"Thouaye M, Yalcin I. Neuropathic pain: from actual pharmacological treatments to new therapeutic horizons. Pharmacol Ther. 2023;251:108546. https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108546.","journal-title":"Pharmacol Ther"},{"key":"1244_CR6","unstructured":"Dahlhamer J, Connor E, Bose J, Lucas J, Zelaya C. Prescription opioid use among adults with chronic pain: United States, 2019. CDC Natl Health Stat Rep. 2021;(162). https:\/\/www.cdc.gov\/nchs\/data\/nhsr\/nhsr162-508.pdf. Accessed 22 Feb 2025."},{"issue":"2","key":"1244_CR7","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(14)70251-0","volume":"14","author":"NB Finnerup","year":"2015","unstructured":"Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14(2):162\u201373. https:\/\/doi.org\/10.1016\/S1474-4422(14)70251-0.","journal-title":"Lancet Neurol"},{"key":"1244_CR8","doi-asserted-by":"crossref","unstructured":"Santo L, Schappert S. Opioids prescribed to adults at discharge from emergency departments: United States, 2017\u20132020. NCHS Data Brief. 2023;(461). https:\/\/www.cdc.gov\/nchs\/data\/databriefs\/db461.pdf. Accessed 18 Mar 2025.","DOI":"10.15620\/cdc:122879"},{"key":"1244_CR9","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1056\/NEJMra1507771","volume":"374","author":"ND Volkow","year":"2016","unstructured":"Volkow ND, McLellan T. Opioid abuse in chronic pain\u2014misconceptions and mitigation strategies. N Engl J Med. 2016;374:1253\u201363. https:\/\/doi.org\/10.1056\/NEJMra1507771.","journal-title":"N Engl J Med"},{"issue":"2","key":"1244_CR10","doi-asserted-by":"publisher","first-page":"131","DOI":"10.7861\/clinmed.2021-0039","volume":"21","author":"FWD Tai","year":"2021","unstructured":"Tai FWD, McAlindon ME. Non-steroidal anti-inflammatory drugs and the gastrointestinal tract. Clin Med. 2021;21(2):131\u20134. https:\/\/doi.org\/10.7861\/clinmed.2021-0039.","journal-title":"Clin Med"},{"key":"1244_CR11","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j1909","volume":"357","author":"M Bally","year":"2017","unstructured":"Bally M, Dendukuri N, Rich B, et al. Risk of acute myocardial infarction with NSAIDs in real-world use: Bayesian meta-analysis of individual patient data. BMJ. 2017;357:j1909. https:\/\/doi.org\/10.1136\/bmj.j1909.","journal-title":"BMJ"},{"issue":"1","key":"1244_CR12","first-page":"20","volume":"26","author":"A O\u2019Neil","year":"2023","unstructured":"O\u2019Neil A. Pharmacological treatment of painful neuropathy in adults with diabetes. Diabet Foot J. 2023;26(1):20\u20133.","journal-title":"Diabet Foot J"},{"issue":"1","key":"1244_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2337\/db2022-01","volume":"2022","author":"R Pop-Busui","year":"2022","unstructured":"Pop-Busui R, Ang L, Boulton AJM, et al. Diagnosis and treatment of painful diabetic peripheral neuropathy. ADA Clin Compendia. 2022;2022(1):1\u201332. https:\/\/doi.org\/10.2337\/db2022-01.","journal-title":"ADA Clin Compendia"},{"issue":"11","key":"1244_CR14","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2215417120","volume":"120","author":"GP Higerd-Rusli","year":"2023","unstructured":"Higerd-Rusli GP, Tyagi S, Baker CA, et al. Inflammation differentially controls transport of depolarizing Nav versus hyperpolarizing Kv channels to drive rat nociceptor activity. Proc Natl Acad Sci USA. 2023;120(11):e2215417120. https:\/\/doi.org\/10.1073\/pnas.2215417120.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1244_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbpa.2024.102538","volume":"76","author":"H Wang","year":"2024","unstructured":"Wang H, Huang J, Zang J, Jin X, Yan N. Drug discovery targeting Nav1.8: structural insights and therapeutic potential. Curr Opin Chem Biol. 2024;76:102538. https:\/\/doi.org\/10.1016\/j.cbpa.2024.102538.","journal-title":"Curr Opin Chem Biol"},{"issue":"4","key":"1244_CR16","first-page":"1607","volume":"100","author":"WA Catterall","year":"2020","unstructured":"Catterall WA, Dib-Hajj S, Choi JS, et al. Voltage-gated sodium channels in pain signaling. Physiol Rev. 2020;100(4):1607\u201345.","journal-title":"Physiol Rev"},{"key":"1244_CR17","first-page":"361","volume":"37","author":"SG Waxman","year":"2014","unstructured":"Waxman SG, Merkies ISJ, Gerrits MM, et al. Sodium channels and pain. Annu Rev Neurosci. 2014;37:361\u201378.","journal-title":"Annu Rev Neurosci"},{"issue":"3","key":"1244_CR18","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1080\/13543784.2020.1728254","volume":"29","author":"M Kushnarev","year":"2020","unstructured":"Kushnarev M, Pirvulescu IP, Candido KD, Knezevic NN. Neuropathic pain: preclinical and early clinical progress with voltage-gated sodium channel blockers. Expert Opin Investig Drugs. 2020;29(3):259\u201371. https:\/\/doi.org\/10.1080\/13543784.2020.1728254.","journal-title":"Expert Opin Investig Drugs"},{"key":"1244_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fnmol.2024.1433981","volume":"17","author":"Y Xiao","year":"2024","unstructured":"Xiao Y, Pan Y, Xiao J, Cummins TR. Molecular determinants of resurgent sodium currents mediated by Nav\u03b24 peptide and A-type FHFs. Front Mol Neurosci. 2024;17:1433981. https:\/\/doi.org\/10.3389\/fnmol.2024.1433981.","journal-title":"Front Mol Neurosci"},{"key":"1244_CR20","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.70173","volume":"11","author":"JL Ransdell","year":"2022","unstructured":"Ransdell JL, Moreno JD, Bhagavan D, Silva JR, Nerbonne JM. Intrinsic mechanisms in the gating of resurgent Na+ currents. Elife. 2022;11:e70173. https:\/\/doi.org\/10.7554\/eLife.70173.","journal-title":"Elife"},{"key":"1244_CR21","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.1523\/JNEUROSCI.0468-18.2018","volume":"39","author":"Y Xiao","year":"2019","unstructured":"Xiao Y, Barbosa C, Pei Z, Xie W, Strong JA, Zhang JM, et al. Increased resurgent sodium currents in Nav1.8 contribute to nociceptive sensory neuron hyperexcitability associated with peripheral neuropathies. J Neurosci. 2019;39:1539\u201350. https:\/\/doi.org\/10.1523\/JNEUROSCI.0468-18.2018.","journal-title":"J Neurosci"},{"key":"1244_CR22","doi-asserted-by":"publisher","first-page":"4825","DOI":"10.1113\/jphysiol.2014.277582","volume":"592","author":"AH Lewis","year":"2014","unstructured":"Lewis AH, Raman IM. Resurgent current of voltage\u2010gated Na+ channels. J Physiol. 2014;592:4825\u201338. https:\/\/doi.org\/10.1113\/jphysiol.2014.277582.","journal-title":"J Physiol"},{"key":"1244_CR23","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1016\/j.bpj.2023.12.016","volume":"123","author":"TK Aman","year":"2024","unstructured":"Aman TK, Raman IM. Resurgent current in context: insights from the structure and function of Na and K channels. Biophys J. 2024;123:1924\u201341. https:\/\/doi.org\/10.1016\/j.bpj.2023.12.016.","journal-title":"Biophys J"},{"key":"1244_CR24","doi-asserted-by":"publisher","first-page":"7190","DOI":"10.1523\/JNEUROSCI.5011-13.2014","volume":"34","author":"ZY Tan","year":"2014","unstructured":"Tan ZY, Piekarz AD, Priest BT, Knopp KL, Krajewski JL, McDermott JS, et al. Tetrodotoxin-resistant sodium channels in sensory neurons generate slow resurgent currents that are enhanced by inflammatory mediators. J Neurosci. 2014;34:7190\u20137. https:\/\/doi.org\/10.1523\/JNEUROSCI.5011-13.2014.","journal-title":"J Neurosci"},{"issue":"6562","key":"1244_CR25","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1038\/379257a0","volume":"379","author":"AN Akopian","year":"1996","unstructured":"Akopian AN, Sivilotti L, Wood JN. A tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons. Nature. 1996;379(6562):257\u201362.","journal-title":"Nature"},{"key":"1244_CR26","unstructured":"Djouhri L, Fang X, Okuse K, et al. The TTX-resistant sodium channel Nav1.8 (SNS\/PN3) is preferentially expressed in nociceptive primary afferent neurons and is resistant to nerve injury-induced downregulation. J Neurosci. 2003;23(18):8445\u20138449."},{"key":"1244_CR27","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1111\/cts.13215","volume":"15","author":"HJ Hijma","year":"2022","unstructured":"Hijma HJ, van Brummelen EMJ, et al. A phase I, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study evaluating the safety, pharmacokinetics and pharmacodynamics of VX-128, a highly selective Nav1.8 inhibitor, in healthy adults. Clin Transl Sci. 2022;15:981\u201393. https:\/\/doi.org\/10.1111\/cts.13215.","journal-title":"Clin Transl Sci"},{"key":"1244_CR28","doi-asserted-by":"publisher","DOI":"10.1177\/1744806919858801","volume":"15","author":"S Hameed","year":"2019","unstructured":"Hameed S. Nav1.7 and Nav1.8: role in the pathophysiology of pain. Mol Pain. 2019;15:1744806919858801. https:\/\/doi.org\/10.1177\/1744806919858801.","journal-title":"Mol Pain"},{"key":"1244_CR29","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1152\/physrev.00052.2017","volume":"99","author":"DL Bennett","year":"2019","unstructured":"Bennett DL, Clark AJ, Huang J, Waxman SG, Dib-Hajj SD. The role of voltage-gated sodium channels in pain signaling. Physiol Rev. 2019;99:1079\u2013151. https:\/\/doi.org\/10.1152\/physrev.00052.2017.","journal-title":"Physiol Rev"},{"key":"1244_CR30","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.pain.2007.07.026","volume":"131","author":"TR Cummins","year":"2007","unstructured":"Cummins TR, Sheets PL, Waxman SG. The roles of sodium channels in nociception: implications for mechanisms of pain. Pain. 2007;131:243\u201357. https:\/\/doi.org\/10.1016\/j.pain.2007.07.026.","journal-title":"Pain"},{"key":"1244_CR31","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.77558","volume":"11","author":"Y Xiao","year":"2022","unstructured":"Xiao Y, Theile JW, Zybura A, Pan Y, Lin Z, Cummins TR. A-type FHFs mediate resurgent currents through TTX-resistant voltage-gated sodium channels. Elife. 2022;11:e77558. https:\/\/doi.org\/10.7554\/eLife.77558.","journal-title":"Elife"},{"issue":"7146","key":"1244_CR32","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1038\/nature05880","volume":"447","author":"K Zimmermann","year":"2007","unstructured":"Zimmermann K, Leffler A, Babes A, et al. Sensory neuron sodium channel Nav1.8 is essential for pain at low temperatures. Nature. 2007;447(7146):855\u20138. https:\/\/doi.org\/10.1038\/nature05880.","journal-title":"Nature"},{"issue":"2","key":"1244_CR33","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1152\/jn.2001.86.2.629","volume":"86","author":"M Renganathan","year":"2001","unstructured":"Renganathan M, Cummins TR, Waxman SG. Contribution of Nav1.8 sodium channels to action potential electrogenesis in DRG neurons. J Neurophysiol. 2001;86(2):629\u201340. https:\/\/doi.org\/10.1152\/jn.2001.86.2.629.","journal-title":"J Neurophysiol"},{"issue":"5","key":"1244_CR34","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJMoa2209870","volume":"389","author":"J Jones","year":"2023","unstructured":"Jones J, Correll DJ, Lechner SM, et al. Selective inhibition of NaV1.8 with VX-548 for acute pain. N Engl J Med. 2023;389(5):393\u2013405. https:\/\/doi.org\/10.1056\/NEJMoa2209870.","journal-title":"N Engl J Med"},{"issue":"1","key":"1244_CR35","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/s0304-3940(98)00738-1","volume":"256","author":"SG Khasar","year":"1998","unstructured":"Khasar SG, Gold MS, Levine JD. A tetrodotoxin-resistant sodium current mediates inflammatory pain in the rat. Neurosci Lett. 1998;256(1):17\u201320. https:\/\/doi.org\/10.1016\/s0304-3940(98)00738-1.","journal-title":"Neurosci Lett"},{"issue":"26","key":"1244_CR36","doi-asserted-by":"publisher","first-page":"9382","DOI":"10.1073\/pnas.0501549102","volume":"102","author":"BT Priest","year":"2005","unstructured":"Priest BT, Murphy BA, Lindia JA, et al. Contribution of the tetrodotoxin-resistant voltage-gated sodium channel NaV1.9 to sensory transmission and nociceptive behavior. Proc Natl Acad Sci USA. 2005;102(26):9382\u20137. https:\/\/doi.org\/10.1073\/pnas.0501549102.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1244_CR37","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nrn3404","volume":"14","author":"SD Dib-Hajj","year":"2013","unstructured":"Dib-Hajj SD, Yang Y, Black JA, Waxman SG. The NaV1.7 sodium channel: from molecule to man. Nat Rev Neurosci. 2013;14:49\u201362. https:\/\/doi.org\/10.1038\/nrn3404.","journal-title":"Nat Rev Neurosci"},{"issue":"4","key":"1244_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0152405","volume":"11","author":"AJ Alexandrou","year":"2016","unstructured":"Alexandrou AJ, Brown AR, Chapman ML, et al. Subtype-selective small molecule inhibitors reveal a fundamental role for Nav1.7 in nociceptor electrogenesis, axonal conduction and presynaptic release. PLoS ONE. 2016;11(4):e0152405. https:\/\/doi.org\/10.1371\/journal.pone.0152405.","journal-title":"PLoS ONE"},{"issue":"38","key":"1244_CR39","doi-asserted-by":"publisher","first-page":"8232","DOI":"10.1523\/JNEUROSCI.2695-04.2004","volume":"24","author":"TR Cummins","year":"2004","unstructured":"Cummins TR, Dib-Hajj SD, Waxman SG. Electrophysiological properties of mutant Nav1.7 sodium channels in a painful inherited neuropathy. J Neurosci. 2004;24(38):8232\u20136. https:\/\/doi.org\/10.1523\/JNEUROSCI.2695-04.2004.","journal-title":"J Neurosci"},{"key":"1244_CR40","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1136\/jmg.2003.012153","volume":"41","author":"Y Yang","year":"2004","unstructured":"Yang Y, Wang Y, Li S, Xu Z, Li H, Ma L, et al. Mutations in SCN9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J Med Genet. 2004;41:171\u20134. https:\/\/doi.org\/10.1136\/jmg.2003.012153.","journal-title":"J Med Genet"},{"key":"1244_CR41","doi-asserted-by":"publisher","first-page":"12706","DOI":"10.1073\/pnas.0404915101","volume":"101","author":"MA Nassar","year":"2004","unstructured":"Nassar MA, Stirling LC, Forlani G, Baker MD, Matthews EA, Dickenson AH, et al. Nociceptor-specific gene deletion reveals a major role for Nav1.7 (PN1) in acute and inflammatory pain. Proc Natl Acad Sci USA. 2004;101:12706\u201311. https:\/\/doi.org\/10.1073\/pnas.0404915101.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1244_CR42","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2024.102433","volume":"75","author":"JJ McDougall","year":"2024","unstructured":"McDougall JJ, O\u2019Brien MS. Analgesic potential of voltage-gated sodium channel modulators for the management of pain. Curr Opin Pharmacol. 2024;75:102433. https:\/\/doi.org\/10.1016\/j.coph.2024.102433.","journal-title":"Curr Opin Pharmacol"},{"issue":"Pt 8","key":"1244_CR43","doi-asserted-by":"publisher","first-page":"1847","DOI":"10.1093\/brain\/awh514","volume":"128","author":"SD Dib-Hajj","year":"2005","unstructured":"Dib-Hajj SD, Rush AM, Cummins TR, et al. Gain-of-function mutation in Nav1.7 in familial erythromelalgia induces bursting of sensory neurons. Brain. 2005;128(Pt 8):1847\u201354. https:\/\/doi.org\/10.1093\/brain\/awh514.","journal-title":"Brain"},{"key":"1244_CR44","unstructured":"SiteOne Therapeutics, Inc. SiteOne therapeutics reports positive phase 1 data for pain treatment Nav1.8 inhibitor STC-004 [Press Release]. Synapse (PatSnap). 2025. https:\/\/synapse.patsnap.com\/article\/siteone-therapeutics-reports-positive-phase-1-data-for-pain-treatment-nav18-inhibitor-stc-004. Accessed 15 Aug 2025."},{"key":"1244_CR45","unstructured":"SiteOne Therapeutics. A phase 1, randomized, double-blind, placebo-controlled single and multiple ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of STC-004. https:\/\/www.anzctr.org.au\/Trial\/Registration\/TrialReview. Accessed 22 May 2025."},{"key":"1244_CR46","unstructured":"Latigo Biotherapeutics. Multiple novel pain programs in development. https:\/\/latigobio.com\/science\/. Accessed 22 May 2025."},{"key":"1244_CR47","unstructured":"Latigo Biotherapeutics. A phase 1 single and multiple ascending dose study of LTG-305 administered orally in healthy participants. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT06554574. Accessed 22 May 2025."},{"key":"1244_CR48","unstructured":"Ozmosi. JMKX-000623 [Drug Profile]. PRYZM Pharma Product Database. 2024. Available online: https:\/\/pryzm.ozmosi.com\/product\/25425. Accessed 15 Aug 2025."},{"key":"1244_CR49","unstructured":"Orion Corporation. Orion Enters into Exclusive Agreement with Jemincare for Novel Non-Opioid Drug Candidate for the Treatment of Pain [Press Release]. Non-Opioid Drug Candidate for the Treatment of Pain Orion Pharma. 2022. https:\/\/www.orionpharma.com\/newsroom\/all-news\/releases\/press-releases\/2022\/orion-enters-into-exclusive-agreement-with-jemincare-for-novel-non-opioid-drug-candidate-for-the-treatment-of-pain\/. Accessed 15 Aug 2025."},{"key":"1244_CR50","unstructured":"Jemincare. Evaluate the efficacy and safety of JMKX000623 in participants with diabetic peripheral neuropathic pain. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT06221241. Accessed 22 May 2025."},{"key":"1244_CR51","unstructured":"AdisInsight. JMKX 000623 [Drug Profile]. Springer Nature. https:\/\/adisinsight.springer.com\/drugs\/800068470. Accessed 15 Aug 2025."},{"key":"1244_CR52","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.pharmthera.2016.11.015","volume":"172","author":"I Vetter","year":"2017","unstructured":"Vetter I, Deuis JR, Mueller A, et al. NaV1.7 as a pain target\u2014from gene to pharmacology. Pharmacol Ther. 2017;172:73\u2013100. https:\/\/doi.org\/10.1016\/j.pharmthera.2016.11.015.","journal-title":"Pharmacol Ther"},{"key":"1244_CR53","unstructured":"Pfizer. Efficacy of Pf-04531083 in treating post-surgical dental pain. ClinicalTrials.gov. https:\/\/www.clinicaltrials.gov\/study\/NCT01512160. Accessed 22 May 2025."},{"key":"1244_CR54","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/s41380-022-01811-4","volume":"28","author":"K Martinowich","year":"2023","unstructured":"Martinowich K, Das D, Sripathy SR, et al. Evaluation of Nav1.8 as a therapeutic target for Pitt Hopkins Syndrome. Mol Psychiatry. 2023;28:76\u201382. https:\/\/doi.org\/10.1038\/s41380-022-01811-4.","journal-title":"Mol Psychiatry"},{"issue":"6","key":"1244_CR55","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1080\/19336950.2015.1079674","volume":"9","author":"SK Bagal","year":"2015","unstructured":"Bagal SK, Marron BE, Owen RM, Storer RI, Swain NA. Voltage-gated sodium channels as drug discovery targets. Channels (Austin). 2015;9(6):360\u20136. https:\/\/doi.org\/10.1080\/19336950.2015.1079674.","journal-title":"Channels (Austin)"},{"issue":"3","key":"1244_CR56","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.neuropharm.2010.05.009","volume":"59","author":"XF Zhang","year":"2010","unstructured":"Zhang XF, Shieh CC, Chapman ML, et al. A-887826 is a structurally novel, potent and voltage-dependent Nav1.8 sodium channel blocker that attenuates neuropathic tactile allodynia in rats. Neuropharmacology. 2010;59(3):201\u20137. https:\/\/doi.org\/10.1016\/j.neuropharm.2010.05.009.","journal-title":"Neuropharmacology"},{"issue":"4","key":"1244_CR57","doi-asserted-by":"publisher","DOI":"10.1085\/jgp.202413719","volume":"157","author":"S Jo","year":"2025","unstructured":"Jo S, Fujita A, Osorno T, Stewart RG, Vaelli PM, Bean BP. Differential state-dependent Nav1.8 inhibition by suzetrigine, LTGO-33, and A-887826. J Gen Physiol. 2025;157(4):e202413719. https:\/\/doi.org\/10.1085\/jgp.202413719.","journal-title":"J Gen Physiol"},{"issue":"8","key":"1244_CR58","doi-asserted-by":"publisher","first-page":"1814","DOI":"10.1093\/pm\/pnab032","volume":"22","author":"HJ Hijma","year":"2021","unstructured":"Hijma HJ, Siebenga PS, de Kam ML, Groeneveld GJ. A phase 1, randomized, double-blind, placebo-controlled, crossover study to evaluate the pharmacodynamic effects of VX-150, a highly selective NaV1.8 inhibitor, in healthy male adults. Pain Med. 2021;22(8):1814\u201326. https:\/\/doi.org\/10.1093\/pm\/pnab032.","journal-title":"Pain Med"},{"key":"1244_CR59","unstructured":"Vertex Pharmaceuticals Incorporated. Vertex announces results from phase 2 study of VX-993 for the treatment of acute pain [Press Release]. Vertex Pharmaceuticals Incorporated, 4 August 2025. https:\/\/investors.vrtx.com\/news-releases\/news-release-details\/vertex-announces-results-phase-2-study-vx-993-treatment-acute. Accessed 23 Aug 2025."},{"issue":"3","key":"1244_CR60","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1124\/molpharm.123.000789","volume":"105","author":"JM Gilchrist","year":"2024","unstructured":"Gilchrist JM, Yang ND, Jiang V, Moyer BD. Pharmacologic characterization of LTGO-33, a selective small molecule inhibitor of the voltage-gated sodium channel NaV1.8 with a unique mechanism of action. Mol Pharmacol. 2024;105(3):233\u201349. https:\/\/doi.org\/10.1124\/molpharm.123.000789.","journal-title":"Mol Pharmacol"},{"issue":"4","key":"1244_CR61","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1124\/molpharm.122.000593","volume":"103","author":"S Jo","year":"2023","unstructured":"Jo S, Zhang H-XB, Bean BP. Use-dependent relief of inhibition of Nav1.8 channels by A-887826. Mol Pharmacol. 2023;103(4):221\u20139. https:\/\/doi.org\/10.1124\/molpharm.122.000593.","journal-title":"Mol Pharmacol"},{"issue":"47","key":"1244_CR62","doi-asserted-by":"publisher","first-page":"10180","DOI":"10.1523\/JNEUROSCI.1049-18.2018","volume":"38","author":"SD Shields","year":"2018","unstructured":"Shields SD, Deng L, Reese RM, et al. Insensitivity to pain upon adult-onset deletion of Nav1.7 or its blockade with selective inhibitors. J Neurosci. 2018;38(47):10180\u2013201. https:\/\/doi.org\/10.1523\/JNEUROSCI.1049-18.2018.","journal-title":"J Neurosci"},{"key":"1244_CR63","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-024-00697-0","author":"JD Osteen","year":"2025","unstructured":"Osteen JD, Immani S, Tapley TL, et al. Pharmacology and mechanism of action of suzetrigine, a potent and selective NaV1.8 pain signal inhibitor for the treatment of moderate to severe pain. Pain Ther. 2025. https:\/\/doi.org\/10.1007\/s40122-024-00697-0.","journal-title":"Pain Ther"},{"issue":"9","key":"1244_CR64","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1080\/17581869.2024.2421749","volume":"14","author":"AY Kong","year":"2024","unstructured":"Kong AY, Tan HS, Habib AS. VX-548 in the treatment of acute pain. Pain Manag. 2024;14(9):477\u201386. https:\/\/doi.org\/10.1080\/17581869.2024.2421749.","journal-title":"Pain Manag"},{"key":"1244_CR65","unstructured":"Vertex Pharmaceuticals Incorporated. Evaluation of Effectiveness, Safety, and Tolerability of SUZ for Acute Pain after Laparoscopic Intraperitoneal Procedures (Clinical Trial Registration No. NCT06887959). ClinicalTrials.gov. Available online: https:\/\/clinicaltrials.gov\/study\/NCT06887959?term=suzetrigine&rank=2. Accessed 23 Aug 2025."},{"key":"1244_CR66","unstructured":"Vertex Pharmaceuticals Incorporated. Evaluation of Effectiveness, Safety, and Tolerability of SUZ as Part of Multimodal Therapy in Treating Acute Postoperative Pain (Clinical Trial Registration No. NCT06887972). ClinicalTrials.gov. Available online: https:\/\/clinicaltrials.gov\/study\/NCT06887972?term=suzetrigine&rank=3. Accessed 23 Aug 2025."},{"key":"1244_CR67","unstructured":"Vertex Pharmaceuticals Incorporated. Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated with Diabetic Peripheral Neuropathy (Clinical Trial Registration No. NCT06628908). ClinicalTrials.gov. 2024. https:\/\/clinicaltrials.gov\/study\/NCT06628908?term=suzetrigine&rank=8. Accessed 23 Aug 2025."},{"key":"1244_CR68","unstructured":"Vertex Pharmaceuticals Incorporated. Evaluation of the Long-Term Safety and Effectiveness of Suzetrigine in Participants with Painful Diabetic Peripheral Neuropathy (Clinical Trial Registration No. NCT06696443). ClinicalTrials.gov. 2024. https:\/\/clinicaltrials.gov\/study\/NCT06696443?term=suzetrigine&rank=7. Accessed 23 Aug 2025."},{"key":"1244_CR69","unstructured":"Hyperway Pharmaceutical Co., Ltd. HBW-004285 \u2013 Phase III clinical study to begin in February 2026, with NDA submission planned for March 2027. BIO International Convention 2025. https:\/\/convention.bio.org\/program-1\/hyperway-pharmaceutical. Accessed 22 May 2025."},{"key":"1244_CR70","doi-asserted-by":"publisher","unstructured":"Uhelski ML, Schaub MK, Espinosa F, Heles M, Cortes N, Li Y, Tatsui CE, Rhines LD, North RY, Alvarez-Breckendridge C, et al. Suzetrigine (VX-548) exhibits activity-dependent effects on human dorsal root ganglion neurons. bioRxiv 2025. https:\/\/doi.org\/10.1101\/2025.04.09.648014.","DOI":"10.1101\/2025.04.09.648014"},{"issue":"3","key":"1244_CR71","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.ejphar.2005.01.030","volume":"510","author":"TC Stummann","year":"2005","unstructured":"Stummann TC, Salvati P, Fariello RG, Faravelli L. Effects of riluzole and related compounds on persistent sodium current in cultured spinal cord neurons. Eur J Pharmacol. 2005;510(3):197\u2013208. https:\/\/doi.org\/10.1016\/j.ejphar.2005.01.030.","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"1244_CR72","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s12640-012-9344-5","volume":"23","author":"AF Di Stefano","year":"2013","unstructured":"Di Stefano AF, Radicioni MM, Rusca A. Pressor response to oral tyramine and monoamine oxidase inhibition during treatment with ralfinamide (NW-1029). Neurotox Res. 2013;23(4):315\u201326. https:\/\/doi.org\/10.1007\/s12640-012-9344-5.","journal-title":"Neurotox Res"},{"issue":"5\u20136","key":"1244_CR73","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1159\/000321322","volume":"86","author":"M Bauer","year":"2010","unstructured":"Bauer M, Bliesath H, Leuratti C, et al. Disposition and metabolism of ralfinamide, a novel Na-channel blocker, in healthy male volunteers. Pharmacology. 2010;86(5\u20136):297\u2013305. https:\/\/doi.org\/10.1159\/000321322.","journal-title":"Pharmacology"},{"key":"1244_CR74","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ejphar.2018.01.041","volume":"823","author":"X Liang","year":"2018","unstructured":"Liang X, Yu G, Su R. Effects of ralfinamide in models of nerve injury and chemotherapy-induced neuropathic pain. Eur J Pharmacol. 2018;823:27\u201334. https:\/\/doi.org\/10.1016\/j.ejphar.2018.01.041.","journal-title":"Eur J Pharmacol"},{"key":"1244_CR75","unstructured":"Newron Pharmaceuticals. Evenamide. Newron Pharmaceuticals. 2025. https:\/\/www.newron.com\/science#evenamide. Accessed 22 May 2025."},{"key":"1244_CR76","doi-asserted-by":"publisher","first-page":"1235","DOI":"10.1038\/s41401-021-00682-9","volume":"42","author":"HL Niu","year":"2021","unstructured":"Niu HL, Liu YN, Xue DQ, et al. Inhibition of Nav1.7 channel by a novel blocker QLS-81 for alleviation of neuropathic pain. Acta Pharmacol Sin. 2021;42:1235\u201347. https:\/\/doi.org\/10.1038\/s41401-021-00682-9.","journal-title":"Acta Pharmacol Sin"},{"issue":"1","key":"1244_CR77","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1021\/acscentsci.3c00016","volume":"9","author":"R Brazil","year":"2023","unstructured":"Brazil R. Peptide nucleic acids promise new therapeutics and gene editing tools. ACS Cent Sci. 2023;9(1):3\u20136. https:\/\/doi.org\/10.1021\/acscentsci.3c00016.","journal-title":"ACS Cent Sci"},{"key":"1244_CR78","unstructured":"OliPass Corporation. Pipeline overview. https:\/\/www.olipass.com\/front\/eng\/competitive\/pipeline.do. Accessed 22 May 2025."},{"key":"1244_CR79","unstructured":"OliPass Corporation. Nav1.7 selective inhibitor OLP-1002 shows strong efficacy and long therapeutic duration according to interim findings from a phase 2a study in OA patients. BioSpace. 2023. Available online: https:\/\/www.biospace.com\/nav1-7-selective-inhibitor-olp-1002-shows-strong-efficacy-and-long-therapeutic-duration-according-to-interim-findings-from-a-phase-2a-study-in-oa-patients. Accessed 15 Aug 2025."},{"key":"1244_CR80","unstructured":"OliPass Corporation. OliPass discloses painful but hilarious clinical findings from a phase 2a trial in OA patients with Nav 1.7 selective Inhibitor OLP-1002 [Press Release]. OliPass Corporation, 13 November 2023. https:\/\/www.prnewswire.com\/news-releases\/olipass-discloses-painful-but-hilarious-clinical-findings-from-a-phase-2a-trial-in-oa-patients-with-nav1-7-selective-inhibitor-olp-1002--301985935.html. Accessed 15 Aug 2025."},{"key":"1244_CR81","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aay9056","volume":"13","author":"AM Moreno","year":"2021","unstructured":"Moreno AM, Alem\u00e1n F, Catroli GF, Hunt M, Hu M, Dailamy A, et al. Long-lasting analgesia via targeted in situ repression of NaV1.7 in mice. Sci Transl Med. 2021;13:eaay9056. https:\/\/doi.org\/10.1126\/scitranslmed.aay9056.","journal-title":"Sci Transl Med"},{"key":"1244_CR82","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1097\/j.pain.0000000000003470","volume":"166","author":"MK Martin","year":"2025","unstructured":"Martin MK, Rodriguez R, Guerrero G, Sheehan GD, Powell R, Klein AH, et al. Pharmacologically enabling the degradation of NaV1.8 channels to reduce neuropathic pain. Pain. 2025;166:1191\u2013203. https:\/\/doi.org\/10.1097\/j.pain.0000000000003470.","journal-title":"Pain"},{"key":"1244_CR83","doi-asserted-by":"publisher","DOI":"10.1101\/2025.02.04.636451","author":"S Tyagi","year":"2025","unstructured":"Tyagi S, Ghovanloo MR, Alsaloum M, Effraim P, Higerd-Rusli GP, Dib-Hajj F, et al. Targeted ubiquitination of NaV1.8 reduces sensory neuronal excitability. bioRxiv. 2025. https:\/\/doi.org\/10.1101\/2025.02.04.636451.","journal-title":"bioRxiv."},{"key":"1244_CR84","unstructured":"iN Therapeutics Co., Ltd. A MAD study to evaluate the safety, tolerability and PK\/PD of iN1011-N17 in healthy volunteers and PHN patients. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT06218784. Accessed 22 May 2025."},{"key":"1244_CR85","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1038\/aps.2017.151","volume":"39","author":"YM Zheng","year":"2018","unstructured":"Zheng YM, Wang WF, Li YF, et al. Enhancing inactivation rather than reducing activation of Nav1.7 channels by a clinically effective analgesic CNV1014802. Acta Pharmacol Sin. 2018;39:587\u201396. https:\/\/doi.org\/10.1038\/aps.2017.151.","journal-title":"Acta Pharmacol Sin"},{"key":"1244_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.101971","volume":"59","author":"CG Faber","year":"2023","unstructured":"Faber CG, Attal N, Lauria G, et al. Efficacy and safety of vixotrigine in idiopathic or diabetes-associated painful small fibre neuropathy (CONVEY): a phase 2 placebo-controlled enriched-enrolment randomised withdrawal study. eClin Med. 2023;59:101971. https:\/\/doi.org\/10.1016\/j.eclinm.2023.101971.","journal-title":"eClin Med"},{"key":"1244_CR87","doi-asserted-by":"publisher","DOI":"10.4172\/2167-0846.S1.002","author":"M Versavel","year":"2015","unstructured":"Versavel M. Efficacy and safety of the novel sodium channel blocker CNV1014802 in trigeminal neuralgia and lumbosacral radiculopathy. J Pain Relief. 2015. https:\/\/doi.org\/10.4172\/2167-0846.S1.002.","journal-title":"J Pain Relief."},{"key":"1244_CR88","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S1474-4422(17)30005-4","volume":"16","author":"JM Zakrzewska","year":"2017","unstructured":"Zakrzewska JM, Palmer J, Morisset V, et al. Safety and efficacy of a Nav1.7 selective sodium channel blocker in patients with trigeminal neuralgia: a double-blind, placebo-controlled, randomised withdrawal phase 2a trial. Lancet Neurol. 2017;16:291\u2013300. https:\/\/doi.org\/10.1016\/S1474-4422(17)30005-4.","journal-title":"Lancet Neurol"},{"key":"1244_CR89","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.2147\/JPR.S247182","volume":"13","author":"M Kotecha","year":"2020","unstructured":"Kotecha M, Cheshire WP, Finnigan H, et al. Design of phase 3 studies evaluating vixotrigine for treatment of trigeminal neuralgia. J Pain Res. 2020;13:1601\u20139. https:\/\/doi.org\/10.2147\/JPR.S247182.","journal-title":"J Pain Res"},{"issue":"17","key":"1244_CR90","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1111\/bph.16398","volume":"181","author":"JV Mulcahy","year":"2024","unstructured":"Mulcahy JV, Beckley JT, Klas SD, et al. ST-2560, a selective inhibitor of the NaV1.7 sodium channel, affects nocifensive and cardiovascular reflexes in non-human primates. Br J Pharmacol. 2024;181(17):3160\u201371. https:\/\/doi.org\/10.1111\/bph.16398.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"1244_CR91","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.pain.2011.09.008","volume":"153","author":"YP Goldberg","year":"2012","unstructured":"Goldberg YP, Price N, Namdari R, et al. Treatment of Na(v)1.7-mediated pain in inherited erythromelalgia using a novel sodium channel blocker. Pain. 2012;153(1):80\u20135. https:\/\/doi.org\/10.1016\/j.pain.2011.09.008.","journal-title":"Pain"},{"issue":"16","key":"1244_CR92","doi-asserted-by":"publisher","first-page":"3690","DOI":"10.1016\/j.bmcl.2014.06.038","volume":"24","author":"SK Bagal","year":"2014","unstructured":"Bagal SK, Chapman ML, Marron BE, et al. Recent progress in sodium channel modulators for pain. Bioorg Med Chem Lett. 2014;24(16):3690\u20139. https:\/\/doi.org\/10.1016\/j.bmcl.2014.06.038.","journal-title":"Bioorg Med Chem Lett"},{"issue":"4","key":"1244_CR93","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/AJP.0000000000000408","volume":"33","author":"N Price","year":"2017","unstructured":"Price N, Namdari R, Neville J, et al. Safety and efficacy of a topical sodium channel inhibitor (TV-45070) in patients with postherpetic neuralgia (PHN): a randomized, controlled, proof-of-concept, crossover study, with a subgroup analysis of the Nav1.7 R1150W genotype. Clin J Pain. 2017;33(4):310\u20138.","journal-title":"Clin J Pain"},{"issue":"2","key":"1244_CR94","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.15761\/GMO.1000126","volume":"2","author":"JMK Hesselink","year":"2018","unstructured":"Hesselink JMK. Topical NaV1.7 channel blocker failed in postherpetic Neuralgia (PHN): lessons to learn. Gen Med Open. 2018;2(2):2515\u20134737. https:\/\/doi.org\/10.15761\/GMO.1000126.","journal-title":"Gen Med Open."},{"issue":"50","key":"1244_CR95","doi-asserted-by":"publisher","first-page":"14693","DOI":"10.1021\/bi7018207","volume":"46","author":"BS Williams","year":"2007","unstructured":"Williams BS, Felix JP, Priest BT, et al. Characterization of a new class of potent inhibitors of the voltage-gated sodium channel Nav1.7. Biochemistry. 2007;46(50):14693\u2013703. https:\/\/doi.org\/10.1021\/bi7018207.","journal-title":"Biochemistry"},{"issue":"12","key":"1244_CR96","doi-asserted-by":"publisher","first-page":"3640","DOI":"10.1016\/j.bmcl.2013.03.121","volume":"23","author":"SB Hoyt","year":"2013","unstructured":"Hoyt SB, London C, Abbadie C, et al. A novel benzazepinone sodium channel blocker with oral efficacy in a rat model of neuropathic pain. Bioorg Med Chem Lett. 2013;23(12):3640\u20135. https:\/\/doi.org\/10.1016\/j.bmcl.2013.03.121.","journal-title":"Bioorg Med Chem Lett"},{"issue":"3","key":"1244_CR97","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1021\/jm3011433","volume":"56","author":"SK Bagal","year":"2013","unstructured":"Bagal SK, Brown AD, Cox PJ, et al. Ion channels as therapeutic targets: a drug discovery perspective. J Med Chem. 2013;56(3):593\u2013624. https:\/\/doi.org\/10.1021\/jm3011433.","journal-title":"J Med Chem"},{"issue":"2","key":"1244_CR98","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/cts.12712","volume":"13","author":"PS Siebenga","year":"2020","unstructured":"Siebenga PS, van Amerongen G, Hay JL, et al. Lack of detection of the analgesic properties of PF-05089771, a selective Nav1.7 inhibitor, using a battery of pain models in healthy subjects. Clin Transl Sci. 2020;13(2):318\u201324. https:\/\/doi.org\/10.1111\/cts.12712.","journal-title":"Clin Transl Sci"},{"issue":"8","key":"1244_CR99","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1097\/j.pain.0000000000001227","volume":"159","author":"A McDonnell","year":"2018","unstructured":"McDonnell A, Collins S, Ali Z, et al. Efficacy of the Nav1.7 blocker PF-05089771 in a randomised, placebo-controlled, double-blind clinical study in subjects with painful diabetic peripheral neuropathy. Pain. 2018;159(8):1465\u201376. https:\/\/doi.org\/10.1097\/j.pain.0000000000001227.","journal-title":"Pain"},{"key":"1244_CR100","doi-asserted-by":"publisher","first-page":"1208","DOI":"10.1038\/s41594-022-00860-1","volume":"29","author":"J Zhang","year":"2022","unstructured":"Zhang J, Shi Y, Huang Z, et al. Structural basis for NaV1.7 inhibition by pore blockers. Nat Struct Mol Biol. 2022;29:1208\u201316. https:\/\/doi.org\/10.1038\/s41594-022-00860-1.","journal-title":"Nat Struct Mol Biol"},{"issue":"19","key":"1244_CR101","doi-asserted-by":"publisher","first-page":"8695","DOI":"10.1021\/acs.jmedchem.8b01906","volume":"62","author":"JV Mulcahy","year":"2019","unstructured":"Mulcahy JV, Pajouhesh H, Beckley JT, et al. Challenges and opportunities for therapeutics targeting the voltage-gated sodium channel isoform NaV1.7. J Med Chem. 2019;62(19):8695\u2013710. https:\/\/doi.org\/10.1021\/acs.jmedchem.8b01906.","journal-title":"J Med Chem"},{"issue":"12","key":"1244_CR102","doi-asserted-by":"publisher","DOI":"10.1111\/cts.70098","volume":"17","author":"KW Chaudhary","year":"2024","unstructured":"Chaudhary KW, Clancy CE, Yang PC, et al. An overview of drug-induced sodium channel blockade and changes in cardiac conduction: implications for drug safety. Clin Transl Sci. 2024;17(12):e70098. https:\/\/doi.org\/10.1111\/cts.70098.","journal-title":"Clin Transl Sci"},{"issue":"Suppl 1","key":"1244_CR103","doi-asserted-by":"publisher","first-page":"S24","DOI":"10.1097\/j.pain.0000000000000854","volume":"158","author":"S Dib-Hajj","year":"2017","unstructured":"Dib-Hajj S, Geha P, Waxman S. Sodium channels in pain disorders: pathophysiology and prospects for treatment. Pain. 2017;158(Suppl 1):S24\u201332. https:\/\/doi.org\/10.1097\/j.pain.0000000000000854.","journal-title":"Pain"},{"key":"1244_CR104","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1161\/CIRCULATIONAHA.123.067331","volume":"149","author":"CP Regan","year":"2024","unstructured":"Regan CP, Morissette P, Kraus RL, Wang E, Arrington L, Vavrek M, et al. Autonomic dysfunction linked to inhibition of the NaV1.7 sodium channel autonomic dysfunction linked to inhibition of the NaV. Circulation. 2024;149:1394\u20136. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.123.067331.","journal-title":"Circulation"},{"key":"1244_CR105","doi-asserted-by":"publisher","first-page":"786078","DOI":"10.3389\/fphar.2021.786078","volume":"12","author":"JE Ballard","year":"2021","unstructured":"Ballard JE, Pall PS, Vardigan J, Zhao F, Holahan MA, Zhou X, et al. Translational pharmacokinetic\u2013pharmacodynamic modeling of Nav1.7 inhibitor MK-2075 to inform human efficacious dose pharmacokinetic-pharmacodynamic modeling of Nav1.7 Inhibitor MKFront. Pharmacology. 2021;12:786078. https:\/\/doi.org\/10.3389\/fphar.2021.786078.","journal-title":"Pharmacology"},{"key":"1244_CR106","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1007\/s40261-019-00807-3","volume":"39","author":"ME Rothenberg","year":"2019","unstructured":"Rothenberg ME, Tagen M, Chang JH, Boyce-Rustay J, Friesenhahn M, Hackos DH, et al. Safety, tolerability, and pharmacokinetics of GDC-0276, a novel Nav1.7 inhibitor, in a first-in-human, single- and multiple-dose study in healthy volunteers. Pharmacokinetics of GDC-0276Clin. Drug Investig. 2019;39:873\u201387. https:\/\/doi.org\/10.1007\/s40261-019-00807-3.","journal-title":"Drug Investig"},{"key":"1244_CR107","doi-asserted-by":"publisher","DOI":"10.3390\/biom15050694","volume":"15","author":"YF Xie","year":"2025","unstructured":"Xie YF. Nav1.8 and chronic pain: from laboratory animals to clinical patients. Biomolecules. 2025;15:694. https:\/\/doi.org\/10.3390\/biom15050694.","journal-title":"Biomolecules"},{"key":"1244_CR108","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.90960","volume":"12","author":"YF Xie","year":"2024","unstructured":"Xie YF, Yang J, Ratt\u00e9 S, Prescott SA. Similar excitability through different sodium channels and implications for the analgesic efficacy of selective drugs. Elife. 2024;12:RP90960. https:\/\/doi.org\/10.7554\/eLife.90960.","journal-title":"Elife"},{"key":"1244_CR109","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2503570122","volume":"122","author":"RG Stewart","year":"2025","unstructured":"Stewart RG, Osorno T, Fujita A, Jo S, Ferraiuolo A, Carlin K, et al. Modulation of human dorsal root ganglion neuron firing by the Nav1.8 inhibitor suzetrigine. Proc Natl Acad Sci USA. 2025;122:e2503570122. https:\/\/doi.org\/10.1073\/pnas.2503570122.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1244_CR110","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1097\/j.pain.0000000000003425","volume":"166","author":"J Yang","year":"2025","unstructured":"Yang J, Xie YF, Smith R, Ratt\u00e9 S, Prescott SA. Discordance between preclinical and clinical testing of NaV1.7-selective inhibitors for pain. Pain. 2025;166:481\u2013501.","journal-title":"Pain"},{"key":"1244_CR111","doi-asserted-by":"publisher","DOI":"10.3390\/life15040640","volume":"15","author":"A Yogi","year":"2025","unstructured":"Yogi A, Banderali U, Moreno MJ, Martina M. Preclinical animal models to investigate the role of Nav1.7 ion channels in pain. Life. 2025;15:640. https:\/\/doi.org\/10.3390\/life15040640.","journal-title":"Life"},{"key":"1244_CR112","unstructured":"Vertex Pharmaceuticals Incorporated. Vertex announces results from phase 2 study of suzetrigine for the treatment of painful lumbosacral radiculopathy [Press Release]. Vertex Pharmaceuticals. 19 December 2024. https:\/\/investors.vrtx.com\/news-releases\/news-release-details\/vertex-announces-results-phase-2-study-suzetrigine-treatment. Accessed 15 Aug 2025."},{"issue":"6433","key":"1244_CR113","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1126\/science.aaw2493","volume":"363","author":"H Shen","year":"2019","unstructured":"Shen H, Liu D, Wu K, Lei J, Yan N. Structures of human Nav1.7 channel in complex with auxiliary subunits and animal toxins. Science. 2019;363(6433):1303\u20138. https:\/\/doi.org\/10.1126\/science.aaw2493.","journal-title":"Science"},{"issue":"11","key":"1244_CR114","doi-asserted-by":"publisher","first-page":"e2100066118","DOI":"10.1073\/pnas.2100066118","volume":"118","author":"X Pan","year":"2021","unstructured":"Pan X, Li Z, Jin X, et al. Comparative structural analysis of human Nav1.1 and Nav1.5 reveals mutational hotspots for sodium channelopathies. Proc Natl Acad Sci USA. 2021;118(11):e2100066118. https:\/\/doi.org\/10.1073\/pnas.2100066118.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1244_CR115","doi-asserted-by":"publisher","first-page":"4976","DOI":"10.1523\/JNEUROSCI.3026-12.2013","volume":"33","author":"JS Bant","year":"2013","unstructured":"Bant JS, Aman TK, Raman IM. Antagonism of lidocaine inhibition by open-channel blockers that generate resurgent Na current. J Neurosci. 2013;33:4976\u201387. https:\/\/doi.org\/10.1523\/JNEUROSCI.3026-12.2013.","journal-title":"J Neurosci"},{"key":"1244_CR116","doi-asserted-by":"publisher","DOI":"10.1172\/JCI194126","volume":"135","author":"TR Cummins","year":"2025","unstructured":"Cummins TR. An approach to targeting Nav1.7 for pain sensations. J Clin Invest. 2025;135:e194126. https:\/\/doi.org\/10.1172\/JCI194126.","journal-title":"J Clin Invest"},{"key":"1244_CR117","doi-asserted-by":"publisher","first-page":"1573254","DOI":"10.3389\/fphar.2025.1573254","volume":"16","author":"R Chen","year":"2025","unstructured":"Chen R, Liu Y, Qian L, et al. Sodium channels as a new target for pain treatment. Front Pharmacol. 2025;16:1573254. https:\/\/doi.org\/10.3389\/fphar.2025.1573254.","journal-title":"Front Pharmacol"},{"issue":"8","key":"1244_CR118","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1517\/14728222.2016.1162295","volume":"20","author":"EC Emery","year":"2016","unstructured":"Emery EC, Luiz AP, Wood JN. Nav1.7 and other voltage-gated sodium channels as drug targets for pain relief. Expert Opin Ther Targets. 2016;20(8):975\u201383. https:\/\/doi.org\/10.1517\/14728222.2016.1162295.","journal-title":"Expert Opin Ther Targets"},{"key":"1244_CR119","doi-asserted-by":"publisher","first-page":"152197","DOI":"10.1016\/j.bbrc.2025.152197","volume":"777","author":"T Kamei","year":"2025","unstructured":"Kamei T, Ishibashi F, Takada Y, Ohno A, Tani N, Ikeda K, et al. A Novel Nav1.7, Nav1.8, and Nav1.9 blocker, ANP-230, has broad analgesic efficacy in preclinical pain models with favorable safety margins. ANP-230, has broad analgesic efficacy in preclinical pain models with favorable safety margins. Biochem Biochem Biophys Res Commun. 2025;777:152197. https:\/\/doi.org\/10.1016\/j.bbrc.2025.152197.","journal-title":"Biochem Biochem. Biophys Res Commun"},{"key":"1244_CR120","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.2147\/JPR.S388896","volume":"16","author":"A Dormer","year":"2023","unstructured":"Dormer A, Narayanan M, Schentag J, et al. A review of the therapeutic targeting of SCN9A and Nav1.7 for pain relief in current human clinical trials. J Pain Res. 2023;16:1487\u201398. https:\/\/doi.org\/10.2147\/JPR.S388896.","journal-title":"J Pain Res"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01244-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01244-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01244-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T08:59:18Z","timestamp":1769677158000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-025-01244-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":120,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1244"],"URL":"https:\/\/doi.org\/10.1007\/s40263-025-01244-x","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"assertion":[{"value":"24 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"C.B., A.S., and N.N.K. declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent (participation and publication)"}},{"value":"Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability statement"}},{"value":"Not applicable","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Conceptualization, N.N.K., C.B., and A.M.; writing\u2014original draft preparation, A.S. and C.B.; writing\u2014review and editing, A.S. and C.B.; visualization, C.B. and A.S.; supervision, N.N.K.; project administration, N.N.K. All authors have read and agreed to the published version of the manuscript.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}